Evidence map›Paper›PMID 39954168›Full record

ReviewEndocrine pathology2025

Clinical Relevance of ATRX/DAXX Gene Mutations and ALT in Functioning Pancreatic Neuroendocrine Tumors.

Brenna R van T Veld, Wenzel M Hackeng, Claudio Luchini, Lodewijk A A Brosens, Koen M A Dreijerink

Abstract readReview
In one paragraph

Review in Endocrine pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Brenna R van T VeldDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0002-4969-0271
Wenzel M HackengDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0001-6795-179X
Claudio LuchiniDepartment of Diagnostics and Public Health, Section of Pathology and ARC-NET Applied Research on Cancer Center, University of Verona, Verona, Italy.ORCID http://orcid.org/0000-0003-4901-4908
Lodewijk A A BrosensDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-1341-8994
Koen M A DreijerinkDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands. k.dreijerink@amsterdamumc.nl.ORCID http://orcid.org/0000-0002-3140-3502

Funding

Maag Lever Darm Stichting WO 22-17
6 · The paper itself

Abstract

Functioning pancreatic neuroendocrine tumors (PanNETs) represent a subset of PanNETs that cause symptoms due to hormonal activity. Insulinoma is the most common functioning PanNET type. Mutations in the alpha thalassemia/mental retardation X-linked (ATRX) and death domain-associated protein (DAXX) genes result in genomic instability. ATRX/DAXX mutations and associated alternative lengthening of telomeres (ALT) are common in non-functioning PanNETs and associated with aggressive tumor behavior. Recent reports have shown that ATRX/DAXX mutations and ALT are also present in functioning PanNETs. In this review, we summarize the literature addressing ATRX/DAXX mutations and ALT in functioning PanNETs and discuss the clinical relevance with regard to distinguishing aggressive and indolent functioning tumors. ATRX/DAXX gene mutations and/or ALT have been reported in insulinoma, glucagonoma, gastrinoma, VIPoma and calcitoninoma. In insulinoma, the presence of ATRX/DAXX mutations and ALT are associated with aggressive behavior and could therefore be used as prognostic biomarkers. Although ATRX/DAXX mutation and ALT assessment may currently not be the standard of care in routine diagnostic pathology practice, the use of DAXX/ATRX immunohistochemistry at least can be encouraged not only for non-functioning but also for functioning PanNETs.

Indexed as

Adaptor Proteins, Signal TransducingNeuroendocrine TumorsNuclear ProteinsPancreatic NeoplasmsTelomere HomeostasisX-linked Nuclear ProteinClinical RelevanceCo-Repressor ProteinsHumansMolecular ChaperonesMutationAdaptor Proteins, Signal TransducingATRX protein, humanCo-Repressor ProteinsDAXX protein, humanMolecular ChaperonesNuclear ProteinsX-linked Nuclear ProteinALTATRXDAXXInsulinomaPancreatic neuroendocrine tumorsPrognostic biomarker

Identifiers

PMID39954168
PMCPMC11829919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.